Breaking Down Lenire’s TENT-A3 Study: A New Hope for Tinnitus Relief with Bimodal Neuromodulation
)
I recently took an in-depth look at the TENT-A3 clinical trial by Neuromod, the creators of the Lenire tinnitus treatment device, so you don’t have to. The study presents a wealth of positive, compelling evidence that led to Lenire’s FDA De Novo approval as a tinnitus treatment. While this is undoubtedly a significant achievement, I have three suggestions on how Neuromod could further strengthen their research and credibility.
What is Tinnitus and How Does Lenire Help?
Tinnitus is an incredibly common condition, affecting 10 to 15% of the U.S. population, or nearly 50 million people. It’s the perception of sound—like ringing or buzzing—without an external source. For some, tinnitus is subtle, but for others, it can be debilitating. Given the impact it can have on quality of life, it’s no surprise that there are countless tinnitus treatments available—many of which lack scientific backing.
)
)
)
)
)